[CAS NO. 1937-19-5]  Aminoguanidine hydrochloride

Aminoguanidine ameliorates neonatal hypoxic-ischemic brain damage and that temporal profiles of NO correlated with the neuroprotective effect of aminoguanidine. Neuroprotection by AG is attributable to suppression of NO produced by iNOS after the end of the hypoxic period, during the reoxygenation phase. The half-life of AG is estimated to be between 6 and 8 h in vivo and approximately 4.4 h in human with normal renal function.AG is also an inhibitor of the formation of advanced glycation end products. Systematically administered advanced glycation end product–modified BSA increases cerebral infarct size in an adult rat, which is attenuated by AG.